AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04303715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No SLNB
Description: BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
Study NCT04303715 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLNB
Description: BCS with SLNB(+/-ALND)
Study NCT04127851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-018 (HA 0.15%)
Description: TJO-018 / one drop / 6 times daily in both eyes
Study NCT04127851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add)
Description: Cyclosporine / one drop / twice daily in both eyes carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes
Study NCT04127851 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%
Description: TJO-018 (HA0.15%)/ one drop 6 times daily in both eyes Cyclosporine 0.05% /one drop twice daily in both eyes
Study NCT03017898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Coagulation
Description: Laser coagulation of anal fistula
Study NCT01226342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical muscle stimulation
Description: On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
Study NCT02217475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: CVC 150 mg, administered orally once daily and taken every morning with food.
Study NCT02217475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily and taken every morning with food.
Study NCT02217475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once daily and taken every morning with food.
Study NCT01288300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Picture good health/Imaginate una buena salud
Description: Diabetes education, self-empowerment training, exercise, patient navigator
Study NCT01288300 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes lecture
Description: Diabetes self-management lecture
Study NCT02402374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma gel
Description: PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
Study NCT02402374 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
Study NCT02175121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily for 28 days
Study NCT02175121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 15 mg, once daily for 28 days
Study NCT02175121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 35 mg, once daily for 28 days
Study NCT02175121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 75 mg, once daily for 28 days
Study NCT02175121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06291874
Description: Tablet, 150 mg, once daily for 28 days
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiYangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine®
Description: Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine®
Description: Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed®
Description: Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed®
Description: Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel®
Description: Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel®
Description: Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
Study NCT02900742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo granules
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
Study NCT03242317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
Study NCT03242317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
Study NCT03525392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-3BP-227 (also called 177Lu-IPN01087)
Description: The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
Study NCT01296802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexfenfluramine
Description: oral, 40 mg to 60 mg, single application as a challenge
Study NCT04168034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iParent2Parent Program
Description: In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.
Study NCT04168034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: The control group will receive standard care but without the iParent2Parent program
Study NCT02484014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tarang Adolescence Education programme
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
Study NCT02484014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tarang Adolescence Education programme
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
Study NCT02484014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEHER Intervention
Description: The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~* Awareness generation activities for all stakeholders in school~* Wall-magazine~* Speak-out box~* Competitions~* School Health Promotion Committee~* School health policies~* Peer groups of students of standard IX~* Workshops and talks for all the students from standard IX, and for teachers~* Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year.
Study NCT02060357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical coherence tomography
Study NCT02517658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Watching a YouTube video containing post tonsillectomy discharge instructions.
Study NCT02517658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard discharge teaching
Description: Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
Study NCT02517658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard discharge teaching
Description: Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
Study NCT00652444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
Study NCT00652444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
Study NCT00652444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Unspecified)
Description: Matching ezetimibe placebo
Study NCT03111524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Communication Resource
Description: The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
Study NCT03111524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention is administered in this group as these are control groups
Study NCT02027025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC1103 low dose
Description: once daily
Study NCT02027025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPARC1103 high dose
Description: once daily
Study NCT02027025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPARC Placebo
Study NCT01296802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexfenfluramine
Description: oral, 40 mg to 60 mg, single application as a challenge
Study NCT03717571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glenohumeral translation assessment
Description: amount of glenohumeral translation under load
Study NCT01012414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: 2 mcg oral paricalcitol daily
Study NCT01012414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00440440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel to be applied daily, starting does 5g.
Study NCT00440440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo gel apply daily
Study NCT02513303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: A single dose of sirolimus delivered locally
Study NCT02513303 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: AV Fistula Surgery
Description: AV Fistula Surgery
Study NCT02513303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AV Fistula Surgery
Description: AV Fistula Surgery
Study NCT02513303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Collagen Implant (SeCI)
Description: SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
Study NCT04716062 — intervention group
Intervention type: PROCEDURE
Intervention: Open or Laparoscopic-assisted Colorectal surgery
Description: Colorectal surgery
Study NCT04368364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine sulfate (ITM)
Description: Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion
Study NCT04368364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Description: Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion
Study NCT04368364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine hydrochloride
Description: Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride
Study NCT01528345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
Study NCT01528345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
Study NCT01528345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
Study NCT01528345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dovitinib Placebo
Description: Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
Study NCT01821352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia Obesity Laser
Description: 10 independent 17 milliwatts 532 nm green diode lasers
Study NCT01821352 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Emits light that has no therapeutic effect
Study NCT03698903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Take a STAND 4 Health
Description: The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
Study NCT03698903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take a STAND 4 Health
Description: The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
Study NCT01580891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftifine HCl Cream 1%
Description: Naftifine HCl Cream 1% applied topically once a day for 28 days.
Study NCT01580891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin® (Naftifine HCl) Cream 1%
Description: Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
Study NCT01580891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical cream
Description: Placebo topical cream applied topically once a day for 28 days.
Study NCT01569672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator matched with subject
Description: Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
Study NCT01569672 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Subjects are mailed informational/educational materials
Description: Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
Study NCT04028726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back-squat exercise
Description: Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
Study NCT04028726 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Back-squat exercise
Description: Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
Study NCT02611947 — intervention group
Intervention type: RADIATION
Intervention: Low-dose chest CT scans
Description: Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm
Study NCT03209479 — intervention group
Intervention type: DRUG
Intervention: Glatiramer acetate
Description: Copaxone subcutaneous injection syringe
Study NCT03301636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
Study NCT03301636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously every 2 weeks starting on day 1.
Study NCT03301636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally every 12 hours starting at Day 1
Study NCT01733277 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: All participants from both arms will be subjected to MRI
Study NCT00623532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body exercises
Study NCT02910050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50mg once a day orally